• 1. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 5. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinecarboxylic acids and derivatives

Research Brief on Ethyl 6-methylpyrimidine-4-carboxylate (CAS: 148149-29-5) in Chemical and Biomedical Applications

Ethyl 6-methylpyrimidine-4-carboxylate (CAS: 148149-29-5) is a pyrimidine derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, including potential therapeutic agents targeting infectious diseases, cancer, and metabolic disorders. Recent studies have explored its utility in the development of novel kinase inhibitors, antimicrobial agents, and modulators of enzymatic activity, positioning it as a valuable scaffold in pharmaceutical research.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of Ethyl 6-methylpyrimidine-4-carboxylate derivatives as selective inhibitors of cyclin-dependent kinases (CDKs), which play crucial roles in cell cycle regulation. The researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's scaffold, resulting in derivatives with improved potency and selectivity against CDK4/6. These findings highlight the potential of 148149-29-5-based compounds in targeted cancer therapies, particularly for breast cancer and other malignancies characterized by CDK dysregulation.

In antimicrobial research, Ethyl 6-methylpyrimidine-4-carboxylate has shown promise as a precursor for novel antibacterial agents. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of hybrid molecules incorporating this pyrimidine core with fluoroquinolone moieties. The resulting compounds exhibited enhanced activity against drug-resistant strains of Staphylococcus aureus and Escherichia coli, with some derivatives showing 8-16 fold greater potency than conventional antibiotics. These results suggest that modifications of the 148149-29-5 scaffold could lead to next-generation antimicrobials addressing the growing challenge of antibiotic resistance.

The compound's role in central nervous system (CNS) drug development has also been investigated. Research published in European Journal of Medicinal Chemistry (2023) explored its derivatives as potential modulators of γ-aminobutyric acid (GABA) receptors. Through molecular docking studies and in vitro assays, scientists identified specific Ethyl 6-methylpyrimidine-4-carboxylate analogs that demonstrated selective binding to GABA_A receptor subtypes, suggesting possible applications in anxiety disorders and epilepsy treatment. These findings open new avenues for developing CNS-active drugs with improved specificity and reduced side effects.

From a synthetic chemistry perspective, recent advancements have focused on developing more efficient and sustainable methods for producing Ethyl 6-methylpyrimidine-4-carboxylate. A 2024 study in Green Chemistry described a microwave-assisted synthesis protocol that reduced reaction times from hours to minutes while maintaining high yields (85-92%). This green chemistry approach not only improves the compound's accessibility for research but also aligns with the pharmaceutical industry's growing emphasis on environmentally friendly manufacturing processes.

Looking forward, the diverse biological activities demonstrated by Ethyl 6-methylpyrimidine-4-carboxylate derivatives suggest continued potential across multiple therapeutic areas. Current research directions include exploring its application in PROTAC (proteolysis targeting chimera) technology and as a building block for covalent inhibitors. As structural biology techniques advance, more precise modifications of the 148149-29-5 scaffold are expected to yield compounds with enhanced pharmacological profiles, potentially leading to clinical candidates in the coming years.

• 2450-08-0(Methyl pyrimidine-4-carboxylate)
• 6345-43-3(4,6-dimethyl pyrimidine-4,6-dicarboxylate)
• 73955-53-0(Methyl 6-methylpyrimidine-4-carboxylate)
• 62846-82-6(Ethyl 4-Pyrimidinecarboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)